Staff report
The recent ICE webinar “Opto Acoustic Imaging a New Modality in Breast Cancer Diagnostics” sponsored by Seno Medical is approved for 1.0 ARRT Category A CE credit by the AHRA.
In this session, Marc Inciardi, MD, discussed how opto-acoustic imaging uses light, sound and artificial intelligence to better diagnose breast cancer by providing functional information in and around a mass. The learning objectives included the benefits patients and clinicians receive from this novel technology that will streamline this care pathway reducing the need for many follow-on exams and biopsies.
Approximately 80 imaging professionals registered for the webinar and attendee Cindy Winter of JPS Health Network in Texas won an ICE gym bag.
Attendees were asked, “Why do you join ICE webinars?”
“Variety of topics, very well organized,” said Jessica Chambers, Regional Service Line Director of Imaging, SSM Health St Louis.
“ICE always provides timely important messages and education,” said Nancy Godby, Director of Radiology, Cabell Huntington Hospital Inc.-Marshall Health Network.
“Excellent speakers and offer CEs,” said Lisa Wood, Executive Director Diagnostic Imaging, Hancock Health.
Inciardi is an associate professor of radiology at the University of Kansas Health System and specializes in breast imaging and intervention. He earned his medical degree and completed a diagnostic residency at the University of Oklahoma Health Sciences Center. He completed a fellowship at the Los Angeles County/USC Medical Center. After working 2 years as assistant professor of radiology at the University of Missouri, Kansas City location, he joined a local private practice group in Kansas City, where he was instrumental in establishing the first community breast center in the Kansas City area. In 2005, he left private practice to assume a full-time breast radiology position at the University of Kansas Health System.
Inciardi was an early adopter of automated breast ultrasound technology (ABUS), participating in the SomoInsight Trial. He has published articles, given various regional/national presentations, and has served as a peer educator for automated breast ultrasound.
Seno Medical Instruments Inc. is a San Antonio, Texas-based medical imaging company committed to improving the efficiency – and reducing the complexity – of breast cancer diagnostics through its new modality: opto-acoustic imaging. Approved by the FDA in January 2021, with supplemental approval in June 2022, Seno’s Imagio Breast Imaging System is a new modality combining light, sound and integrated AI to provide information not previously available to the breast imager. The result is substantially improved confidence in diagnostic results that leads to real-time assessments, streamlined care pathways, and reductions in false positive biopsies. The company was recently recognized by Frost & Sullivan with its 2023 Enabling Technology Leadership award for its innovative approach to diagnostic imaging.
For more information, including upcoming webinars, visit ICEwebinars.live.
